BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

945 related articles for article (PubMed ID: 18220786)

  • 1. Predictive QSAR modeling workflow, model applicability domains, and virtual screening.
    Tropsha A; Golbraikh A
    Curr Pharm Des; 2007; 13(34):3494-504. PubMed ID: 18220786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From drug target to leads--sketching a physicochemical pathway for lead molecule design in silico.
    Shaikh SA; Jain T; Sandhu G; Latha N; Jayaram B
    Curr Pharm Des; 2007; 13(34):3454-70. PubMed ID: 18220783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of AmpC beta-lactamase binders vs. decoys using classification kNN QSAR modeling and application of the QSAR classifier to virtual screening.
    Hsieh JH; Wang XS; Teotico D; Golbraikh A; Tropsha A
    J Comput Aided Mol Des; 2008 Sep; 22(9):593-609. PubMed ID: 18338225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of validated QSAR models of D1 dopaminergic antagonists for database mining.
    Oloff S; Mailman RB; Tropsha A
    J Med Chem; 2005 Nov; 48(23):7322-32. PubMed ID: 16279792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QSAR modeling of GPCR ligands: methodologies and examples of applications.
    Tropsha A; Wang SX
    Ernst Schering Found Symp Proc; 2006; (2):49-73. PubMed ID: 17703577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virtual high-throughput screening of molecular databases.
    Seifert MH; Kraus J; Kramer B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):298-307. PubMed ID: 17554856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds.
    Shen M; Béguin C; Golbraikh A; Stables JP; Kohn H; Tropsha A
    J Med Chem; 2004 Apr; 47(9):2356-64. PubMed ID: 15084134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Analysis of QSAR-based vs. Chemical Similarity Based Predictors of GPCRs Binding Affinity.
    Luo M; Wang XS; Tropsha A
    Mol Inform; 2016 Jan; 35(1):36-41. PubMed ID: 27491652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Best Practices for QSAR Model Development, Validation, and Exploitation.
    Tropsha A
    Mol Inform; 2010 Jul; 29(6-7):476-88. PubMed ID: 27463326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On various metrics used for validation of predictive QSAR models with applications in virtual screening and focused library design.
    Roy K; Mitra I
    Comb Chem High Throughput Screen; 2011 Jul; 14(6):450-74. PubMed ID: 21521150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial QSAR modeling of specificity and subtype selectivity of ligands binding to serotonin receptors 5HT1E and 5HT1F.
    Wang XS; Tang H; Golbraikh A; Tropsha A
    J Chem Inf Model; 2008 May; 48(5):997-1013. PubMed ID: 18470978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modeling of hydration in drug design.
    Mancera RL
    Curr Opin Drug Discov Devel; 2007 May; 10(3):275-80. PubMed ID: 17554853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
    Martin E; Mukherjee P; Sullivan D; Jansen J
    J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QSAR classification model for antibacterial compounds and its use in virtual screening.
    Singh N; Chaudhury S; Liu R; AbdulHameed MD; Tawa G; Wallqvist A
    J Chem Inf Model; 2012 Oct; 52(10):2559-69. PubMed ID: 23013546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
    Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
    J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4D- quantitative structure-activity relationship modeling: making a comeback.
    Fourches D; Ash J
    Expert Opin Drug Discov; 2019 Dec; 14(12):1227-1235. PubMed ID: 31513441
    [No Abstract]   [Full Text] [Related]  

  • 17. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of protein-ligand interaction fingerprints in docking.
    Brewerton SC
    Curr Opin Drug Discov Devel; 2008 May; 11(3):356-64. PubMed ID: 18428089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring conformational search protocols for ligand-based virtual screening and 3-D QSAR modeling.
    Cappel D; Dixon SL; Sherman W; Duan J
    J Comput Aided Mol Des; 2015 Feb; 29(2):165-82. PubMed ID: 25408244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.